Long Term Study With B2036-PEG
A phase 3 trial of Pegvisomant in Pituitary tumours, run by Pfizer, completed.
Overview
Long Term Study With B2036-PEG is a phase 3 interventional study registered as NCT00143416 by Pfizer, with 16 participants recorded, started 2004-04. Interventions recorded: Pegvisomant. Conditions recorded: Acromegaly.
Linked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStrict IGF-1 Control in Acromegaly
Shares Pegvisomant, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialLanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Shares Pegvisomant, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialMulticenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStudy of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialCabergoline in Nonfunctioning Pituitary Adenomas
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Potency of a High Cabergoline Dosage in Microprolactinomas
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.